References
- Alkonyi B., Chugani HT., Juhasz C.:
Transient focal cortical increase of interictal glucose metabolism in Sturge-Weber syndrome: implications for epileptogenesis . Epilepsia, 2011, 52: 1265–1272. - Arun D., Gutmann D.H.:
Recent advances in neurofibromatosis 1. Curr. Opin. Neurol., 2004, 17: 101–105. - Arzimanoglou A., Aicardi J.:The epilepsy of Sturge-Weber syndrome: clinical features and treatment in 23 patients. Acta Neurol. Scand., Suppl., 1992, 140: 18–22.
- Barba C., Jaques T., Kahane P., Polster T., Isnard J., Leijten F.S. et al.:Epilepsy surgery in Neurofibromatosis Type 1. Epilepsy Res., 2013, 105: 384–395.
- Bebin E.M., Gomez M.R.:
Prognosis in Sturge-Weber disease: comparison of unihemisspheric and bihemispheric involvement . J. Child. Neurol., 1992, 3: 181–184. - Benedikt R.A., Brown D.C., Walker R., Ghaed V.N., Mitchell M., Geyer C.A.:Sturge-Weber syndrome: cranial MR imaging with Gd-DTPA. Am. J. Neurorad., 1993, 14: 1409–1415. Chugani H.T., Luat A.F., Kumar A., Govindan R., Pawlik K., Asano E.:α-[11C]-Methyl-L-tryptophan-PET in 191 patients with tuberous sclerosis complex. Neurology, 2013, 81: 674–680. Chu-Shore C.J., Major P., Camposano S., Muzykewicz D., Thiele E.A.:The natural history of epilepsy in tuberous sclerosis complex. Epilepsia, 2010, 51: 1236–1241.
- Comi A.M.:
Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies . Lymphat. Res. Biol., 2007, 5: 257–264. - Comi A.M., Bellamkonda S., Ferenc L.M., Cohen B.A., Germain-Lee E.L.:Central hypothyroidism and Sturge-Weber syndrome. Pediatr. Neurol., 2008, 39: 58–62.
- Crumrine P.K.:
Mamagement of seizures in Lennox-Gastaut syndrome . Paediatr. Drugs., 2011, 13: 107–118. - Curatolo P., Bombardieri R., Jóźwiak S.:
Tuberous sclerosis . Lancet, 2008, 372: 657–668. - Curatolo P., Jóźwiak S., Nabbout R.:Management of epilepsy associated with tuberous sclerosis complex (TSC): Clinical recommendations. Eur. J. Paediatr. Neurol., 2012, 16: 582–586.
- DiFrancesco J.C., Sestini R., Cossu F., Bolognesi M., Sala E., Mariani S. et al.:Novel neurofibromatosis type 2 mutation presenting with status epilepticus. Epileptic Disord., 2014, 16: 132–137.
- Domańska-Pakieła D., Kaczorowska M., Jurkiewicz E., Kotulska K., Dunin-Wąsowicz D., Jóźwiak S.:EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients-A prospective study of 5 patients. Eur. J. Paediatr. Neurology, 2014, 18: 458–468.
- Kossoff E.H., Borsage J.L., Comi A.L.:
A pilot study of the modified Atkins diet for Sturge-Weber syndrome . Epilepsy Res., 2010, 92: 240–243. - Elliot R.E., Carlson C., Kalhorn S.P., Moshel Y.A., Weiner H.L., Devinsky O. et al.:
Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery . Epilepsy Behav., 2009, 16: 454–460. - Fallah A., Guyatt G.H., Snead O.C., Ebrahim S., Ibrahim G.M., Mansouri A. et al.:Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis. PLoS One., 2013, 8: e53565.
- Franz D.N., Belousova E., Sparagana S., Bebin E.M., Frost M., Kuperman R. et al.:Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2013, 381: 125–132.
- Friedman D., Bogner M., Parker-Menzer K., Devinsky O.:
Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex . Epilepsy Behav., 2013, 27: 118–120. Guerreiro M.M., Andermann F., Andermann E., Palmini A., Hwang P., Hoffman H.J. et al.:Surgical treatment of epilepsy in tuberous sclerosis . Neurology, 1998, 51: 1263–1269. - Gurecki P.J., Holden K.R., Sahn E.E., Dyer D.S., Cure J.K.:
Developmental neural abnormalities and seizures in epidermal nevus syndrome . Dev. Med. Child. Neurol., 1996, 38: 716–723. - Happle R.:
Epidermal nevus syndrome . Semin. Dermatol., 1995, 14: 111–121. - Hennel S.J., Ekkert P.G., Volpe J.J., Inder T.E.:Insights into the pathogenesis of cerebral lesions in incontinentia pigmenti. Pediatr. Neurol., 2003, 29: 148–150.
- Hsieh H.Y., Fung H.C., Wang C.J., Chin S.C., Wu T.:Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure, 2011, 20: 606–611.
- Humphrey A., MacLean C., Ploubidis GB., Granader Y., Clifford M., Haslop M. et al.:
Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis . Epilepsia, 2014, 55: 108–116. Hyman S.L., Gill D.S., Shores E.A., Steinberg A., Joy P., Gibikote S.V. et al.:Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1. Neurology, 2003, 60: 1139–1145. - Ito M.:Studies of melanin IX. Incontinentia pigmenti achromians, a singular case of naevus depigmentosis systematicus bilateralis. Tohoku J. Exp. Med., 1952, 55: 57–59.
- Jagtap S., Srinivas G., Harsha K.J., Radhakrishnan N., Radhakrishnan A. et al.:Sturge-Weber syndrome: clinical spectrum, disease course, and outcome of 30 patients. J. Child. Neurol., 2013, 28: 725–731.
- Jansen F.E., van Huffelen A.C., Algra A., van Nieuwenhuizen O.:Epilepsy surgery in tuberous sclerosis: a systematic review. Epilepsia, 2007, 48: 1477–1484.
- Jóźwiak J., Jóźwiak S., Włodarski P.:
Possible mechanisms of disease development in tuberous sclerosis . Lancet Oncology, 2008, 9: 73–79. - Jóźwiak S., Kossoff E.H., Kotulska-Jóźwiak K.:Dietary treatment of epilepsy: rebirth of an ancient treatment. Neurol. Neurochir. Pol., 2011a, 45: 370–378.
- Jóźwiak S., Kotulska K., Domańska-Pakieła D., Łojszczyk B., Syczewska M., Chmielewski D. et al.:Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur. J. Paediatr. Neurol., 2011b, 15: 424–431.
- Jóźwiak S.:Epilepsy and mental retardation in tuberous sclerosis complex – can we prevent them? In: T. Takahashi and Y. Fukuyama, Biology of Seizure Susceptibility in Developing Brain, John Libbey Eurotext, Montrouge 2008.
- Kossoff E.H., Thiele E.A., Pfeifer H.H., McGrogan J.R., Freeman J.M.:
Tuberous sclerosis complex and the ketogenic diet. Epilepsia, 2005, 46: 1684–1686. - Kossoff E.H., Buck C., Freeman J.M.:Outcomes of 32 hemi-spherectomies for Sturge-Weber syndrome worldwide. Neurology, 2002, 59: 1735–1738.
- Kossoff E.H., Ferenc L., Comi A.M.:
An infantile-onset, severe, yet sporadic seizure pattern is common in Sturge-Weber syndrome . Epilepsia, 2009, 50: 2154–2157. - Kothare S.V., Singh K., Chalifoux J.R., Staley B.A., Weiner H.L., Menzer K. et al.:Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia, 2014, Jun 10. doi: 10.1111/epi.12680. [Epub ahead of print].
- Kotulska K., Chmielewski D., Borkowska J., Jurkiewicz E., Kuczyński D., Kmieć T. et al.:Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur. J. Paediatr. Neurology., 2013, 17: 479–485.
- Krsek P., Jahodova A., Kyncl M., Kudr M., Komarek V., Jezdik P. et al.:
Predictors of seizure-free outcome after epilepsy surgery for pediatric tuberous sclerosis complex . Epilepsia, 2013, 54: 1913–1921. - Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P. et al.:
Everolimus for subependymal giantcell astrocytomas in tuberous sclerosis . N. Engl. J. Med., 2010, 363: 1801–1811. - Krueger D.A., Wilfong AA., Holland-Bouley K., Anderson A.E., Agricola K., Tudor C. et al.:
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex . Ann. Neurol., 2013, 74: 679–687. - Kulkantrakorn K., Geller T.:Seizures in neurofibromatosis 1. Pediatr. Neurol., 1998, 19: 347–350.
- Kwiatkowski D.J., Manning B.D.:
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways . Hum. Mol. Genet., 2005, 4: 251–258. - Lazarowski A., Ramos A.J., Garcia-Rivello H., Brusco A., Girardi E.:
Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model . Cell. Mol. Neurobiol., 2004, 24: 77–85. - Ma T.S., Elliott R.E., Ruppe V., Devinsky O., Kuzniecky R., Weiner H.L., Carlson C.:
Electrocorticographic evidence of perituberal cortex epileptogenicity in tuberous sclerosis complex . J. Neurosurg. Pediatr., 2012, 10: 376–382. - Maher C.O., Cohen-Gadol A.A., Raffel C.:Cortical resection for epilepsy in children with linear sebaceous nevus syndrome. Pediatr. Neurosurg., 2003, 39: 129–135.
- Major P., Thiele E.A.:
Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex . Epilepsy Behav., 2008, 13: 357–360. - Menon G., Nair S., Sudhir J., Rao B.R., Mathew A., Bahuleyan B.:Childhood and adolescent meningiomas: a report of 38 cases and review of literature. Acta Neurochir., 2009, 151: 239–244. Menor F., Marti-Bonmati L., Arana E.:Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur. J. Radiol., 1998, 26: 121–131. Meuwissen M., Mancini G.:
Neurological findings in incontinentia pigmenti; a review . Eur. J. Med. Genet., 2012, 55: 323–331. - Muncy J., Butler I.J., Koenig M.K.:Rapamycin reduces seizures frequency in tuberous sclerosis complex. J. Child. Neurology, 2009, 24: 477.
- Nehal K.S., PeBenito R., Orlow S.J.:Analysis of 54 cases of hypopigmentation and hyperpigmentation along the lines of Blaschko. Arch. Dermatol., 1996, 132: 1167–1170.
- North K.N.:Clinical aspects of neurofibromatosis 1. Eur. J. Paediatr. Neurol., 1998, 2: 223–231.
- Northrup H., Krueger D.A.:International Tuberous Sclerosis Complex Consensus Group. Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49: 243–254.
- O’Callaghan F.J., Harris T., Joinson C., Bolton P., Noakes M., Presdee D. et al.:The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch. Dis. Child., 2004, 89: 530–533.
- Ostendorf A.P., Gutmann D.H., Weisenberg J.L.:Epilepsy in individuals with neurofibromatosis type 1. Epilepsia, 2013, 54: 1810–1814.
- Parisi P., Bombardieri R., Curatolo P.:Current role of vigabatrin in infantile spasms. Eur. J. Paediatr. Neurol., 2007, 11: 331–336.
- Pascual-Castroviejo I., Pascual-Pascual S.I., Velazquez-Fragua R., Viano J.:Sturge-Weber syndrome: study of 55 patients. Can. J. Neurol. Sci., 2008, 35: 301–307.
- Pavonne L., Curatolo P., Rizzo R., Micali G., Incorpora G., Garg B.P. et al.:
Epidermal nevus syndrome: a neurologic variant with hemimegalancephaly, gyral malformation, mental retardation, seizures and facial hemihypertrophy . Neurology, 1991, 41: 266–271. - Perek-Polnik M., Jóźwiak S., Jurkiewicz E., Perek D., Kotulska K.:Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. Eur. J. Paediatr. Neurol., 2012, 16: 83–85.
- Roach E.S.:
Neurocutaneous syndromes . Pediatr. Clin. North. Am., 1992, 39: 591–620. - Rubi S., Costes N., Heckemann R.A., Bouvard S., Hammers A., Marti-Fuster B. et al.:Positron emission tomography with α-[11C]methyl-L-tryptophan in tuberous sclerosis complex-related epilepsy. Epilepsia, 2013, 54: 2143–2150.
- Shen M.H., Harper P.S., Upadhyaya M.:
Molecular genetics of neurofibromatosis type 1 (NF1) . J. Med. Genet., 1996, 33: 2–17. Shepherd C.W. Gomez M.R., Lie J.T, Crowson C.S.:Causes of death in patients with tuberous sclerosis . Mayo Clin. Proc., 1991, 66: 792–796. - Shirley M.D., Tang H., Gallione C.J., Baugher J.D., Frelin L. P., Cohen B. et al.:
Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ . N. Eng. J. Med., 2013, 368: 1971–1979. - Sparagana S.P., Delgado M.R., Batchelor R.R., Roach E.S.:Seizure remission and antiepileptic drug discontinuation in children with tuberous sclerosis complex. Arch. Neurol., 2003, 60: 1286–1289.
- Sujansky E., Conradi S.:Outcome of Sturge-Weber syndrome in 52 adults. Am. J. Med. Genet., 1995, 57: 35–45.
- Talos D.M., Sun H., Zhou X., Fitzgerald E.C., Jackson M.C., Klein P.M. et al.:The interaction between early life epilepsy and autistic-like behavioralconsequences: a rolefor the mammalian target of rapamycin (mTOR) pathway. PLoS One, 2012, 7: e35885.
- Thiele E.A.:Managing epilepsy in tuberous sclerosis complex. J. Child. Neurol., 2004, 19: 680–686.
- Ville D., Enjolras O., Chiron C., Dulac O.:
Prophylactic antiepileptic treatment in Sturge-Weber disease . Seizure, 2002, 11: 145–150. - Vivarelli R., Grosso S., Calabrese F., Farnetani M., Galluzzi P., Vatti G.P. et al.:
Epilepsy in neurofibromatosis 1. J. Child. Neurol., 2003, 18: 338–342. - Webb D.W., Fryer A.E., Osborne J.P.:
Morbidity associated with tuberous sclerosis: a population study . Dev. Med. Child. Neurol., 1996, 38: 146–155. - Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D.:
Treatment of pediatric epilepsy: European expert opinion, 2007 . Epileptic Disord., 2007, 9: 353–412. - Wiederholt W.C., Gomez M.R., Kurland L.T.:Incidence and prevalence of tuberous sclerosis in Rochester, Minnesota, 1950 through 1982. Neurology, 1985, 35: 600–603.
- Wong M.:
Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies . Epilepsia, 2010, 51: 27–36. - Wu J.Y., Salamon N., Kirsch H.E., Mantle M.M., Nagarajan S.S., Kurelowech L. et al.:
Noninvasive testing, early surgery and seizure freedom in tuberous sclerosis complex . Neurology, 2010, 74: 392–398. - Yates J.R.:
Tuberous sclerosis . Eur. J. Hum. Genet., 2006, 14: 1065–1073. - Zhang B., McDaniel S.S., Rensing N.R., Wong M.:Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One, 2013, 8: e57445.